सत्यमेव जयते

Dr. G. N. Singh
DRUGS CONTROLLER GENERAL (INDIA)

Central Drugs Standard Control Organization
Directorate General of Health Services
Ministry of Health & Family Welfare
Tele – 011-23236965, Fax: 011 -23236973
Email: **dci@nic.in**
FDA Bhavan, Kotla Road, New Delhi –110002

F. No. X-19013/2/2017-DC

Dated 29 SEP 2017

To

All State/UT Drug Controllers

Sub: Report of the 52nd Meeting of the Drugs Consultative Committee held on 18th September, 2017 at New Delhi -110002- reg.

Sir,

52nd meeting of the Drugs Consultative Committee was held on 18th September, 2017 at New Delhi – 110002.

The Report of the 52nd meeting of the Drugs Consultative Committee held on 18th September, 2017 is annexed herewith for your information and taking further necessary action, wherever required as per recommendations decided therein.

Yours faithfully,

(Dr. G. N. Singh)
Drugs Controller General (India)

Encl. Copy of the minutes

Copy forwarded for information to:-

1. Zonal / Sub-zonal offices of CDSCO
2. Drugs Testing Labs of CDSCO
3. PPS to DGHS
4. PPS to JS(R)

REPORT OF 52ND MEETING OF DRUGS CONSULTATIVE COMMITTEE HELD ON 18TH SEPTEMBER, 2017 AT NEW DELHI

Inaugural Deliberations

(LIST OF PARTICIPANTS IS AT ANNEXURE I)

Dr. G. N. Singh, Drugs Controller General (India) and Chairman, Drugs Consultative Committee, welcomed and greeted the participants. He informed the members about various initiatives taken by CDSCO and Ministry in the recent past to strengthen the drug regulatory system in the country. He briefed the members about various amendments in the D&C Rules relating to regulation of Drugs and Medical Devices in recent months.

DCG (I) requested all State Drugs Controllers to appraise about the implementation of earlier decisions deliberated in the 51st DCC regarding the signing of MOU with Central Govt., implementation of regulations for ease of doing business, sharing of online information regarding manufacturing, sales and product licences for uploading on CDSCO website, harmonization of drug regulatory system having uniform pay scales and infrastructure etc.

Members suggested to develop a common software database for issuance of licences comprising list of approved, unapproved and banned drugs. The software should have the capability of detecting the applications containing unapproved or banned drugs in full or part.

The Director General, Drugs Control Administration, Andhra Pradesh, explained about the challenges he is facing for implementation of D& C Rules as the State Govt. is not having any permanent office. He also requested to have a dedicated office of CDSCO at Vishakhapatnam (Vizag), as most of the imports and exports are now being carried out from Vizag Sea and airports. He also mentioned about the issue of antibiotic resistance due to the usage of feed supplements in most of the coastal districts of Andhra Pradesh, where there is no regulation for misuse of antibiotics in the feed supplements and other non-medicinal items used in pisiculture.

The Drugs Controllers, Odisha, Goa, Gujarat, Maharashtra, Nagaland and other states expressed their concerns regarding non-release of the allotted funds as-

sured in the earlier meetings to strengthen their regulatory system within their targeted timeframe.

DCG (I) requested Dr. Ravi Shankar, DG, DCA, AP; Dr. R.A Singh, Director, CDTL Chandigarh; Dr. Raman Mohan Singh, Director, CDTL, Mumbai and Shri. C Hariharan, Director, CDL, Kolkata to make a proposal for cadre based posts for all the drugs testing laboratories keeping in view, the inter laboratories transfer policy, creation of additional posts for all laboratories, transfer of posts of laboratories from one state to the another/ Centre etc.

Members also requested DCG(I) to provide at least one mobile testing laboratory to each State under the Central Govt. Scheme. This matter will be taken up to the Ministry to allocate 20 mobile testing labs to States and 20 mobile testing labs at CDSCO Zonal /Sub-zonal/ Port offices for rapid screening of the medical products. Dr. Bangarurajan, DDC (WZ) will be the coordinator, with Dr. R.A Singh, Director, CDTL Chandigarh for setting up of mobile testing laboratories. Specifications of these mobile labs will be on lines of FSSAI initiatives for the food mobile testing laboratories.

Members also requested to create National Intelligence Agency to coordinate all State Nodal Officers. DCC recommended to constitute a sub-committee under supervision of Dr. Bangarurajan, DDC (I), WZ for constitution of National Intelligence Agency. Dr. Ravi Shankar, DG, DCA, AP, Shri. O.S Sadhwani, Jt. Commissioner, FDA, Maharashtra and Shri. Salim A. Veljee, Drugs Controller, Goa will also be putting their inputs for the same. NIA may comprise of one DI / ADC from every subzone and the respective States. If needed experts from outside may be included for efficient investigation. Members also requested to create a police system specially allotted for helping NIA. NIA may also include lawyers and income tax officers as per the requirement. Members requested to conduct a workshop on creation and functioning of NIA.

DCG (I) also briefed about a draft on various policy issues relating to drug regulations. Dr. S.E. Reddy, JDC (I), CDSCO discussed in detail the following points of the policy for inclusion of these issues in the draft NPP, 2017:

1. Public confidence on quality of drugs;
2. Autonomy for Drug Regulators;
3. Creation of Indian Pharmaceutical Services;
4. High powered Advisory Body;

5. Policy on Fixed Dose Combinations (FDC) / Clinical Trials / Medical Devices;
6. Approach towards International Cooperation;
7. Role of regulators in promotion of innovation;
8. Maintenance of regulatory data;
9. Strengthening the Pharmacy practice;
10. Strengthening of drugs regulatory system;
11. Strengthening of regulations;
12. Policy on online pharmacy;
13. Promotion of generics; and
14. Policy for prohibition of drugs due to lack of rationality, lack of efficacy etc.

DCC deliberated the above points in detail and agreed to forward the draft on above points with certain minor changes to the MoHFW requesting the Ministry for consideration and to take necessary action for implementation in the NPP, 2017.

1. AGENDA

CONSIDERATION FOR APPROVAL OF REPORT OF 51ST DCC MEETING HELD ON 09.06.2017 AND ACTION TAKEN IN THE MATTERS ARISING OUT OF THE MEETING

The report of the 51st meeting of the DCC was considered acceptable with certain suggestions as given below:

Ag. No.	SUBJECT	ACTION TAKEN
I & II	**INAUGURAL DELIBERATIONS**	
1.	Cadre restructuring in State Drugs Controls for uniform implementation of provisions of the Drugs and Cosmetics Act, 1940 and Rules, 1945 • The post of Drugs Inspector should be re-designated as Drugs Control Officer. • The grade pay of Assistant Drugs Inspector should be raised to Rs.4800 in Pay Band-2. • The grade pay of Drugs Inspector should be raised to Rs.5400 in Pay Band-2. • All the other higher posts should be accordingly reorganized.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed. But some of the members of DCC suggested that the Grade pay of Rs. 5400 was implemented in only three states and the remaining states have so far not taken up the issue. Also it was requested to forward a letter to Chief Secretaries of all State Govt. from a senior official of Central Govt.

Ag. No.	SUBJECT	ACTION TAKEN
2.	The Central Govt. should issue direction to the State Governments to ensure adequate regulatory officials which will be commensurate with the number of sale outlets and manufacturing units located in the respective States considering that there should be one official for every 200 sale outlets and one official for every 50 manufacturing units.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed. However, it was suggested by all members of DCC to replace "One official" with "One Drugs Control Officer" and DCC agreed for the same.
3.	There should be provisions for deputation of State regulatory officials to the Central regulatory system and vice versa.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed. The members also suggested to have senior positions on deputation from State to Centre and vice-versa and accordingly an official letter may be addressed to all Chief Secretaries through Ministry for implementation.
4.	The minimum experience for Licensing Authorities (LA) relating to manufacturing and sale of drugs should be raised adequately.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
5.	The practice of having multiple LA in a State for regulation of manufacture of drugs may be replaced by a single LA with provision for delegation of powers to other regulatory officials.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
6.	Guidelines, directions as and when issued, should be communicated to the State Government and not to the State Drugs Controllers for ensuring effective uniform implementations of such guidelines directions.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed. However, it was suggested by all members of DCC to replace: "not to" with "also" and DCC agreed for the same
7.	It was suggested that Drugs Control Authority of each State should create an Intelligence cell with a Nodal Officer for market surveillance and conducting investigation in respect of Spurious, adulterated drugs in coordination with CDSCO.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed. However, it was suggested by all members of DCC to replace the word "Intelligence cell" with "Investigation cell" and DCC agreed for the same.
8.	Drugs samples from supply chain of procurement agencies needs focused monitoring for ensuring quality of the drugs.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
9.	The procurement agencies get their sample tested at approved private drug testing laboratories and obtain test reports in Form 39, which is supposed to be issued by such laboratories only to drug manufacturers who do not have testing facilities. The Drugs and Cos-	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.

Ag. No.	SUBJECT	ACTION TAKEN
	metics Rules, 1945 should be amended to prescribe a separate Form for issuing test reports by such laboratories for procurement agencies.	
10.	The committee while appreciating the recently conducted National Drugs Survey mentioned that a system should be put in place to address the issues, if any, relating to the Survey, when brought to the notice of the authority.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
11.	Guidelines should be prepared for disposal of expired drugs a committee comprising Drugs Controllers of Telangana, MP and DDC (I), Hyderabad zone should be constituted in this regard.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.Accordingly DCG (I) has constituted a sub-committee with the DDC (I) CDSCO Hyderabad, DC Telangana and DC Madhya Pradesh. The sub-committee members prepared draft guidelines for disposal of expired drugs and submitted for consideration. However, DCC members did not agree to the proposal of sending the expired drugs to the manufacturer but recommended that the disposal of expired drugs should be at respective sales outlets.
12.	Weak areas of market identified on the basis of risk analysis and intelligence information shall be kept under active quality surveillance of GAP by conducting special operations.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
13.	Regulatory officials should not participate in the procurement activities as there may be conflict of interest.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
14.	Minutes of all DCC and DTAB meetings held so far should be compiled and uploaded in CDSCO website.	This matter was taken up in 77th DTAB held on 16.06.2017 and agreed.
III	**AGENDA**	
1.	Consideration for approval of report of 50th DCC meeting held on 4th & 5th November 2016 and action taken in the matters arising out of the meeting	Report of the 50th meeting of the DCC was considered approved.
2.	An update on the central scheme for strengthening of the States Drugs departments under 12th five year plan	Agreed
3.	An update on Medical Devices Rules, 2017	Agreed
4.	An update on risk based inspection evaluation of manufacturing facilities for ensuring quality of medicines by monitoring of GMP compliance	Agreed

Ag. No.	SUBJECT	ACTION TAKEN
5.	An update on the issue of misuse of oxytocin by dairy owners to extract milk from milch animals	Agreed
6.	Consideration for regulation of pathology and clinical diagnostic laboratories in India	DCG (I) during inaugural meeting has emphasized on creation of standards for pathological diagnostics laboratories under the Drugs & Cosmetics Rules, 1945, on lines of Clinical Establishments (Registration and Regulation) Act, 2010 for uniform implementation under supervision of Dr. V.G. Somani, JDC (I), CDSCO, Shri. Sudipta Dey, DDC (I), CDSCO (HQ) and Shri. O.S Sadhwani, Jt. Commissioner, FDA Maharashtra.

2. AGENDA

CONSIDERATION OF THE PROPOSAL OF SELF-CERTIFICATION BY THE PHARMACEUTICAL UNITS FOLLOWED BY THIRD-PARTY CERTIFICATION AND DETAILED AUDIT ON THE ISSUE OF UNIVERSAL ADOPTION OF GOOD MANUFACTURING PRACTICES (GMP) BY THE PHARMACEUTICAL SECTOR

DCC deliberated the matter and agreed to the proposal of self-certification by the pharmaceutical units followed by third-party certification and detailed audit on the issue of universal adoption of Good Manufacturing Practices (GMP) by the pharmaceutical sector.

In this regard DCG(I) has issued notice to all drug manufacturers on 09-08-2017 regarding self-certification. A comprehensive checklist for self-inspection is already available on CDSCO website.

Further, the DCC requested all the State Licensing Authorities to pursue with the licencees to submit the details of self-certification so that the same can be uploaded on CDSCO website.

3. AGENDA

CONSIDERATION OF THE PROPOSAL TO EXPLORE THE FEASIBILITY OF PROVIDING A SEPARATE SHELF/RACK FOR GENERIC MEDICINES IN PHARMACY

DCC deliberated the matter and agreed to the proposal of having a provision of a dedicated shelf/rack for generic medicines in every pharmacy so as to promote the availability of “Generic Medicines”.

4. AGENDA

CONSIDERATION OF AGENDA FOR CREATION OF SEPARATE PROVISION FOR OVER THE COUNTER (OTC) DRUGS TO BE SOLD ON RETAIL PHARMACIES ETC

DCC after deliberation recommended for creation of a separate category of OTC drugs to be sold in retail pharmacies. Further, DCC recommended for constitution of a sub-committee comprising of following members.

1. Dr. Ravi Shankar IPS, Drugs Controller, Andhra Pradesh
2. Drugs controller, Chandigarh
3. Drugs controller, Uttarakhand
4. Drugs controller, Karnataka
5. Joint Director, FDA, Mizoram
6. DDC(I), R. Chandrashekhar (Convener)

The committee shall examine comprehensively the drugs marketed in country vis-à-vis conditions for sale stipulated under various schedules, namely H, H1, G, X, K and recommend the list of drugs which may be considered for marketing as OTC along with conditions to be followed.

5. AGENDA

REVIEW OF PROPHYLACTIC DOSES MENTIONED UNDER SCHEDULE ‘V’ OF DRUGS AND COSMETICS RULES VIS A VIS THE DOSES PRESCRIBED UNDER FOOD SAFETY AND STANDARDS ACT.

DCC deliberated the agenda and recommended that a provision may be incorporated in Drugs and Cosmetics Rules especially in Sch ‘V’ and Sch ‘K’ to ex-

clude multivitamin preparations containing vitamins in a strength which is lower than Recommended Daily Allowance (RDA) for Indians as recommended by ICMR and FSSAI, from the provisions of Drugs and Cosmetics Rules.

6. AGENDA

CONSIDERATION OF SUGGESTIONS OF INDUSTRY ASSOCIATION IN VARIOUS ISSUES AS UNDER

a) ISSUE OF GENERAL EXPORT NOC AND MANUFACTURING LICENCE FOR NEW DRUG AND BANNED DRUG INSTEAD OF QUANTITY AND COUNTRY SPECIFIC NOC AND LICENCE BASED ON EXPORT ORDER

DCC recommended that the proposal may be forwarded to Ministry of Health and Family for consideration and approval.

b) COPP / FSC FOR EXPORT& (c) MARKET AUTHORIZATION FOR DOMESTIC TENDERS

DCC agreed for a timeline of 3 working days for processing of such applications provided the application is complete. However, the number of products in one application should not be more than 10.

d) ONLINE GRANT OF NOC / COPP / FSC / PRODUCT PERMISSION FOR EXPORTS

Online application processing for COPP/ Blood bank license under SUGAM Portal is already under advanced stage of implementation.

e) MANUFACTURE OF DIFFERENT TYPES OF MEDICINES IN SAME FACILITY

DCC did not agree to the proposal as the conditions of license will be different for different types of medicines.

f) MERGING OF VARIOUS FORMS FOR MANUFACTURING LICENCES

The DCC agreed for the common format as proposed in Agenda no. 13 (Annexure VI).

g) SHELF LIFE OF FORMULATION SHOULD NOT BE LINKED WITH THE SHELF LIFE OF BULK

DCC did not agree to the proposal.

7. AGENDA

CONSIDERATION OF THE PROPOSAL TO AMEND SCHEDULE M UNDER DRUGS & COSMETICS RULES, 1945 TO BRING THE PHARMACOVIGILANCE PROGRAM OF INDIA (PvPI) UNDER STATUTORY REQUIREMENT

The agenda will be taken up in the next DCC meeting.

8. AGENDA

CONSIDERATION OF AGENDA REGARDING COMPILATION OF DATA OF MANUFACTURERS AND PRODUCTS LICENSED IN INDIA AND EXTENSION OF E-GOVERNANCE FACILITIES "SUGAM" OF CDSCO TO ALL STATE DRUG CONTROLLERS FOR UPLOADING SUCH DATA

DCC deliberated the matter regarding compilation of data of manufacturers and products licensed in India and extension of e-Governance facilities "SUGAM" of CDSCO to all State Drug Controllers for uploading such data. The members were requested to take all necessary measures so that such data are uploaded in the SUGAM portal at the earliest.

9. AGENDA

CONSIDERATION OF PROPOSAL TO ADDRESS THE ISSUE OF VERIFICATION OF GLOBAL ENTRY PROGRAMME (GEP) APPLICANT - BY U.S. CUSTOMS AND BORDER PROTECTION (U.S. CBP) DEPARTMENT

The agenda will be taken up in the next DCC meeting.

10. AGENDA

AN UPDATE ON THE RECOMMENDATIONS OF 51st DCC FOR DISPOSAL OF EXPIRED DRUGS UNDER THE DRUGS & COSMETICS RULES, 1945 SUBMITTED BY SUB-COMMITTEE

The agenda will be taken up in the next DCC meeting.

11. AGENDA

AN UPDATE ON THE ISSUE OF MISUSE OF OXYTOCIN BY DAIRY OWNERS TO EXTRACT MILK FROM MILCH ANIMALS

All the State Licensing Authorities were once again requested to keep a continuous vigil on the licences issued for manufacturing and sales of Oxytocin in their states and update regularly to CDSCO.

12. AGENDA

CONSIDERATION OF THE AGENDA ON THE ISSUE OF ABUSE OF PHARMACEUTICAL PRODUCTS

DCC deliberated the issue of abuse of pharmaceutical products including codeine based cough syrups and other narcotic drugs. Dr. Rajender Pal Singh Deputy Director General (Operations), Narcotics Control Bureau, made a detailed presentation regarding the illicit trafficking of narcotic drugs.

The DCC requested all the State Drugs Controllers to extend their cooperation for curbing the misuse of narcotic drugs with specific emphasis on codeine phosphate syrups, tramadol etc.

13. AGENDA

CONSIDERATION OF THE PROPOSAL REGARDING THE FORMAT FOR APPROVAL OF DRUGS TO BE ANNEXED WITH VARIOUS DRUGS MANUFACTURING LICENSES & STANDARDISATION OF WHO-GMP, COPP FORMATS

Members agreed to the proposal to have a common format with same size, font, colour, background logo on white paper as given in **ANNEXURE VI** of the Agenda. Any further suggestions in this regard are also invited from all the SLAs.

14. AGENDA

CONSIDERATION OF THE PROPOSAL FOR REVISION OF THE FEES FOR THE TEST OR ANALYSIS BY AMENDING SCHEDULE B AND SCHEDULE B-1 OF DRUGS AND COSMETICS RULES

The agenda will be taken up in the next DCC meeting.

15. AGENDA

CONSIDERATION OF PROPOSAL TO INCLUDE THE ADVERTISEMENTS FOR TREATMENT OF THE AILMENTS MENTIONED IN SCHEDULE J UNDER DRUGS & COSMETICS RULES AND IN DRUGS AND MAGIC REMEDIES (OBJECTION-ABLE ADVERTISEMENTS) ACT, 1954 & RULES 1955

The agenda will be taken up in the next DCC meeting.

16. AGENDA

PROPOSAL FROM ODISHA

The agenda will be taken up in the next DCC meeting.

17. AGENDA

PROPOSAL FROM GOA

The agenda will be taken up in the next DCC meeting.

The meeting ended with the vote of thanks to the Chair.

ANNEXURE I

List of the participants of 52nd Drugs Consultative Committee meeting held on 18th September, 2017 at New Delhi under the Chairmanship of Dr. G. N. Singh, Drugs Controller General (India)

A. STATE/UTs DRUGS CONTROL ORGANIZATIONS

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
1.	Dr. Ravi Shankar, DG, DCA, Andhra Pradesh
2.	Shri. G. Tayen S. A.D.C Arunachal Pradesh
3.	Shri. Ravindra Kumar Singh, State Drugs Controller, Bihar
4.	Shri. Hiren Patel, FDA, Chhattisgarh
5.	Shri. Salim A, Veljee, Director, FDA, Goa
6.	Dr. H.G. Koshia, Commissioner, FDCA, Gujarat
7.	Shri. Narendra Kumar Ahooja, Assist. State Drugs Controller, Haryana,
8.	Shri. Navneet Marwaha, Drugs Controller, Himachal Pradesh
9.	Ms. Lotika Khajuria, Dy. Controller, Jammu & Kashmir
10.	Smt. Ritu Sahay, Director (Drugs), Jharkhand
11.	Shri. B.T. Khanapure, Drugs Controller (HQ), Karnataka
12.	Shri. Shobhit Dy. DC, FDA, Madhya Pradesh.
13.	Shri. O. S. Sadhwani, Jt. Commissioner (HQ), FDA, Maharashtra
14.	Shri. A.T. Nikhade, Jt. Commissioner (HQ), FDA, Maharashtra
15.	Shri. Akoijam Singhajeet Singh, State Drugs Controller &LA, Manipur
16.	Shri. Devistone Swer, Assist. Drugs Controller, Meghalaya
17.	Shri Lal Sawma, Joint Director, FDA, Mizoram
18.	Shri. W.H. Patton, Jt. Drugs Controller, Nagaland
19.	Shri H. Mahapatra, Drugs Controller, Odisha
20.	Shri. Pradeep Kumar, Jt. Commissioner, FDA, Punjab
21.	Shri K. Sivabalan, Director, DCA, Tamil Nadu
22.	Dr. N. Goswami, Dy. Drugs Controller, Tripura
23.	Shri Gulshan Setia, Assist. Commissioner (Drugs), Bareilly Division, UP
24.	Shri. Tejbir Singh, Drugs Controller, Uttarakhand

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
25.	Shri. Amit Duggal, Sr.DCO, Chandigarh
26.	Shri. Balram Sahu, Drugs Control Department, Delhi
27.	Shri. Atul Kumar Nasa, Controlling Authority, Delhi

B. INVITEE

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
28.	Shri. Dr. Rajender Pal Singh, DDG (Ops), NCB New Delhi.

C. DRUG TESTING LABORATORIES

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
29.	Shri. C Hariharan,, Director/In-Charge, CDL, Kolkata
30.	Dr. Arun Bhardwaj, Director, CRI, Kasauli
31.	Dr. Raman Mohan Singh, Director, CDTL, Mumbai
32.	Dr. N. Murugesan, Director, CDTL, Chennai/Hyderabad
33.	Dr. R. A. Singh, Director, RDTL, Chandigarh

D. ZONAL/ SUB ZONAL OFFICES OF CDSCO

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
34.	Shri. Arvind Kukrety, DDC(I), Ahmedabad zone
35.	Shri. P.B.N. Prasad, DDC (I), Hyderabad Zone
36.	Shri A. K. Pradhan, DDC(I), North Zone (Ghaziabad)
37.	Dr. Naresh Sharma, ADC(I), North Zone (Ghaziabad)
38.	Dr. S. Manivannan , DDC(I), South Zone (Chennai)
39.	Dr. K. Bangarurajan, DDC(I), West Zone (Mumbai)
40.	Shri. B.K. Samantray, DDC(I), Sub-zone (Baddi)
41.	Smt. Shanthy Gunashekharan, DDC(I), Sub-zone (Bangalore)
42.	Shri Sanjeev Kumar, DDC(I), Sub-zone (Indore)

E. CDSCO HEAD QUARTER

S. No.	NAME AND ADDRESS OF THE PARTICIPANTS
43.	Dr. G. N. Singh, DCG(I)
44.	Dr. S. Eswara Reddy, JDC(I)
45.	Dr. V. G. Somani, JDC(I),
46.	Shri. Arun Sharma, Dir. (Admin)
47.	Shri A. C. S. Rao, DDC(I)
48.	Shri. A.K. Pradhan, DDC(I)
49.	Dr. S.P. Shani, DDC(I)
50.	Smt. Annam Visala, DDC(I)
51.	Shri. R. Chandrashekhar, DDC(I)
52.	Shri. Aseem Sahu, DDC(I)
53.	Shri. Sudipta Dey, DDC(I)
54.	Smt. Rubina Bose, DDC(I)
55.	Shri. B. Kumar, DDC(I)
56.	Smt. Swati Srivastava, DDC(I)
57.	Dr. Santosh V. Indraksha, ADC(I)
58.	Shri. Prakash Kumar Parida, DI
59.	Shri Raghuvaran Gunda, DI
60.	Ms. Gunja Chaturvedi, ADI